FDA Approves UCB's RYSTIGGO as First Drug for Myasthenia Gravis Treatment
TL;DR
The FDA has approved UCB's Rystiggo, a treatment for generalized myasthenia gravis, making it the first drug to receive approval for both main subtypes of the rare autoimmune disease. UCB plans to make the under-the-skin treatment commercially available in the third quarter, following the recent approval of argenx's Vyvgart Hytrulo in subcutaneous form.
- FDA approves first of two UCB myasthenia gravis drugs, following Alexion and argenx's lead Endpoints News
- FDA approves rozanolixizumab, known as Rystiggo, to treat gMG |... Myasthenia Gravis News
- UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis UCB
- Myasthenia Gravis Drug Gets FDA Nod Medscape
- UCB myasthenia gravis drug given FDA approval Labiotech.eu
Want the full story? Read the original reporting
Read on Endpoints News